Dermatofibrosarcoma protuberans is a soft tissue sarcoma that is dermal in origin. The incidence is <0.1% of all malignancies and 1% of soft tissue sarcoma. Most commonly, it involves trunk (62%) followed by extremities (25%) and head and neck (13%). It is a slow growing tumor with locally aggressive behavior. Here, a 50-year-old female diagnosed with orbital dermatofibrosarcoma developed extra-axial component in right frontal region even on chemotherapy. Hence, the bad prognostic factors are yet to be established in dermatofibrosarcoma protuberans.
Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma which is dermal in origin, accounting for <0.1% of malignant lesions and 1% of soft tissue sarcoma. [1] It is locally aggressive and extends into the subcutaneous tissues and muscles. [2] It usually occurs in the second to sixth decade of life and males are more affected compared to females. [3] Here, we are presenting a rare case of orbital DFSP with frontal and ethmoid sinus invasion.
Case Report
A 50-year-old female presented in the radiation oncology OPD in May 2014 with complaints of swelling on the medial aspect of the right eye, slowly progressive for the last 4 months and associated with pain and diminution of vision. She also had episodes of nasal bleeding for the past 2 months. There was no other complaint of vomiting, dizziness, headache, seizures, or dyspnea. On clinical examination, approximately, 5 cm × 5 cm swelling was present over right medial canthus, displacing right eye outward with ulceration of cornea and swelling of lower eyelid, another 2 cm × 2 cm firm swelling was also present over the medial canthus of the left eye. There was no preauricular or cervical lymphadenopathy [ Fig. 1 ].
A direct nasal endoscopy (DNE) was suggestive of the right uncinar polypoidal polyp arising from medial turbinate. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. Brief Communications the dose of imatinib has been increased to 800 mg/day. On the last follow-up, disease was stable on tablet imatinib 800 mg/day.
Discussion
The annual incidence of DFSP ranges from 0.8 to 5 cases/ million population. [4] It is dermal in origin and presents as a plague/papule which develops into lumpy nodule over time. It usually occurs in trunk (62%), followed by extremities (25%) and head and neck region (13%). [5] In 90% of DFSP, there is reciprocal translocation at t(17;22)(q22;q13) leading to the fusion of genes collagen Type I, alpha 1, and platelet-derived growth factor (PDGF) beta-chain resulting in activation of PDGF receptor protein tyrosine kinase. The diagnosis of DFSP is confirmed by histopathology in which proliferation of spindle cells embedded in collagen and arranged in storiform or cartwheel pattern is characteristic. DFSP is CD34 and vimentin positive. [3] Fibrous histiocytomas are the most common orbital tumors in adults. They develop insidiously and can be locally infiltrating, and although they are benign lesions, their rate of recurrence is high. These are characterized by a proliferation of fusiform cells in the dermis, constituted by a variable combination of fibroblasts, collagen, histiocytes, and blood vessels. They are usually CD34 negative. Hemangiopericytomas usually appear in young and middle age and appear histologically as dense, hypercellular tumors with spindle-shaped cells. The tumors are vascular with a variably dilated, vascular branching pattern classically described as "staghorn vessels." [6] The treatment of choice in DFSP is surgical excision. [7] Mohs micrographic surgery is preferred as it preserves cosmesis. [8] Radiation therapy is used in adjuvant setting up to a dose of 50-60 Gy in case of a positive margin or residual disease. [9] In the present case, as the lesion was inoperable, the patient was planned for palliative radiation therapy.
Alternate treatment option for DFSP is chemotherapy. A PDGF receptor inhibitor, imatinib mesylate has been used in the past in case of locally advanced or metastatic disease. [9, 10] Other tyrosine kinase inhibitors such as sunitinib and nilotinib have been developed. DFSP of orbit is very rare. So far, only six case reports have been published in literature [ Table 1 ]. In all six cases, surgery was the main modality of treatment except in a study by Bashir et al. in which adjuvant radiotherapy of 60 Gy in 30 fractions was given as adjuvant therapy followed by adjuvant chemotherapy with imatinib mesylate 800 mg/day. [14] 
Conclusion
To the best of our knowledge, this study is the first in which DFSP of orbit has been extended to involve the frontal and ethmoid sinuses. Being inoperable and locally advanced, it was decided to continue with palliative radiotherapy followed by therapy with imatinib mesylate.
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